Tenderwize
Back to tender search

Open house Arzneimittelrabattverträge Certolizumab pegol, ATC L04AB05

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Apr 05, 2027 · 232 days left·Open·Supplies·Framework
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Certolizumab pegol, ATC L04AB05

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

50 / 100

Complexity

20 / 100

Risk factors

The open-house model is not subject to procurement law; potential legal uncertainty regarding contract stability.

No indication of discount rates or market size; profitability depends on negotiated discounts and volume.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Provision of Certolizumab pegol (ATC L04AB05) under a discount agreement with AOK Bayern
  • Agreement to a fixed discount model; terms are predefined and non-negotiable
Show full summary

This is an open-house model (not a formal procurement procedure) by AOK Bayern for non-exclusive discount agreements on the pharmaceutical active substance Certolizumab pegol (ATC L04AB05). Any interested pharmaceutical company that meets the eligibility criteria can join. The contract duration is from 01.06.2025 to 31.05.2027. No estimated value is provided. Submission can be in paper form or electronically with a qualified electronic signature. The contract is automatically terminated if a regular procurement discount agreement for the same substance comes into effect.

Risks

The open-house model is not subject to procurement law; potential legal uncertainty regarding contract stability.

No indication of discount rates or market size; profitability depends on negotiated discounts and volume.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical company (pharmazeutischer Unternehmer)

Administrative

  • Submit signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
  • Submit signed contract and attachment specifying the medicinal products

Requirements may be incomplete.

Award Criteria

Lot 1

No award criteria; this is an open-house model with no selection.

Buyer

Location

München, DEU

Website

www.aok.de

Buyer profile

Open profile

Identifier

DE811695320

Activity

Health

Lots (1)

LOT-0001

Open house Arzneimittelrabattverträge Certolizumab pegol, ATC L04AB05

Non-exclusive discount agreements for Certolizumab pegol. Open to all qualified pharmaceutical companies. Contracts are identical and non-negotiable.

SuppliesFrameworkEU fundedElectronic submission

Location

DE212, Germany

Duration

May 2025 - May 2027

Category

Pharmaceutical products

Award Criteria

No award criteria; this is an open-house model with no selection.

Deadline

Deadline Apr 05, 2027

Procurement Details

Publication date
15 Apr 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
246855-2025

Documents (2)

Similar tenders